ロード中...
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacting disease outcome. Over the last years myeloid derived sup...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217777/ https://ncbi.nlm.nih.gov/pubmed/30396365 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0432-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|